Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study-Reference-Cited by-同舟云学术

Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study

Published:2024-01-01 Issue:1 Volume:34 Page:26-40
ISSN:1050-7256
Container-title:Thyroid®
language:en
Short-container-title:Thyroid®

Author:

Subbiah Vivek¹^ORCID,Hu Mimi I.²,Mansfield Aaron S.³,Taylor Matthew H.⁴,Schuler Martin⁵,Zhu Viola W.⁶,Hadoux Julien⁷^ORCID,Curigliano Giuseppe⁸⁹,Wirth Lori¹⁰,Gainor Justin F.¹⁰,Alonso Guzman¹¹,Adkins Douglas¹²,Godbert Yann¹³,Ahn Myung-Ju¹⁴,Cassier Philippe A.¹⁵,Cho Byoung Chul¹⁶,Lin Chia-Chi¹⁷,Zalutskaya Alena¹⁸,Barata Teresa¹⁹,Trask Peter²⁰,Scalori Astrid²¹,Bordogna Walter¹⁹,Heinzmann Sebastian¹⁹,Brose Marcia S.²²

Affiliation:

1. Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

2. Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

3. Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.

4. Developmental Cancer Therapeutics Laboratory, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon, USA.

5. Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.

6. Department of Medicine, University of California Irvine, Orange, California, USA.

7. Department of Endocrine Oncology, Gustave Roussy, Villejuif, France.

8. Clinical Division of Early Drug Development, European Institute of Oncology, IRCCS, Milano, Italy.

9. Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy.

10. Center for Head and Neck Cancers, Massachusetts General Hospital, Boston, Massachusetts, USA.

11. Early Drug Development Unit, Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain.

12. Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.

13. Nuclear Medicine and Thyroid Oncology Department, Bergonié Institute Cancer Center, Bordeaux, France.

14. Department of Hematology and Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

15. Department of Medical Oncology, Centre Léon Bérard, Lyon, France.

16. Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.

17. Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.

18. Blueprint Medicines Corporation, Cambridge, Massachusetts, USA.

19. F. Hoffmann-La Roche Ltd., Basel, Switzerland.

20. Genentech, Inc., South San Francisco, California, USA.

21. F. Hoffmann-La Roche Ltd., Welwyn Garden City, United Kingdom.

22. Departments of Otorhinolaryngology; Head and Neck Surgery, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Publisher

Mary Ann Liebert Inc

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/thy.2023.0363

Reference22 articles.

1. RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients

2. RET/PTC Rearrangements and BRAF Mutations in Thyroid Tumorigenesis

3. Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma

4. Medullary thyroid carcinoma: The third most common thyroid cancer reviewed

5. New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with doubleRETmutations